Chest, Vol 99, 551-556, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension

JM Morgan, M Griffiths, RM du Bois and TW Evans
Department of Thoracic Medicine, National Heart and Lung Institute, London, England.

Reduction of pulmonary vascular resistance by a high inspired oxygen concentration is a common, but not universal phenomenon in patients with pulmonary vascular disease of varying etiology that may determine their response to long-term domiciliary oxygen therapy. We therefore determined changes in PVR during oxygen therapy in two patient populations not previously studied: systemic sclerosis (n = 8, mean age +/- SEM, 44.5 +/- 5.4 years) and primary pulmonary hypertension (n = 7, mean age +/- SEM 38 +/- 7.8 years). All patients were hypoxemic (arterial oxygen tension, on air 9.5 +/- 1.2 kPa for SSc and 8.3 +/- 0.6 kPa for PPH, p greater than 0.05). Right atrial pressure, pulmonary artery pressure, pulmonary artery occlusion pressure, systemic arterial pressure, PaO2 and cardiac output by thermodilution were measured at three, 20-min intervals while inspiring air and again after inspiring 60 percent oxygen for 30 min. The PVR fell significantly with oxygen in patients with SSc from 797.6 +/- 179.2 to 610 +/- 151.6 dynes/s/cm-5 (p less than 0.01), and this fall correlated with baseline PAP and PaO2 prior to oxygen therapy (r = 0.86, p less than 0.025; r = 0.77, p less than 0.05, respectively). In patients with PPH, there was no significant fall in PVR with oxygen (from 969 +/- 80.2 to 851.9 +/- 91.2 dynes/s/cm-5, p greater than 0.05) and no predictor of a vasodilator response in individual patients. In SSc, hypoxic pulmonary vasoconstriction contributes more consistently to elevated PVR than in patients with PPH.

This article has been cited by other articles:

				K. B. Highland, C. Strange, J. Mazur, and K. N. Simpson Treatment of Pulmonary Arterial Hypertension: A Preliminary Decision Analysis Chest, December 1, 2003; 124(6): 2087 - 2092. [Abstract] [Full Text] [PDF]

				P. Maddison Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition Rheumatology, September 1, 2002; 41(9): 965 - 971. [Abstract] [Full Text] [PDF]

				D. H. Roberts, J. J. Lepore, A. Maroo, M. J. Semigran, and L. C. Ginns Oxygen Therapy Improves Cardiac Index and Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension Chest, November 1, 2001; 120(5): 1547 - 1555. [Abstract] [Full Text] [PDF]

				J. MANDEL, E. J. MARK, and C. A. HALES Pulmonary Veno-occlusive Disease Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1964 - 1973. [Full Text]

				C. Strange, M. Bolster, J. Mazur, M. Taylor, J. R. Gossage, and R. Silver Hemodynamic Effects of Epoprostenol in Patients With Systemic Sclerosis and Pulmonary Hypertension Chest, October 1, 2000; 118(4): 1077 - 1082. [Abstract] [Full Text] [PDF]

				A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]

				O. Sanchez, M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary hypertension secondary to connective tissue diseases Thorax, March 1, 1999; 54(3): 273 - 277. [Full Text]